<div class="docx-content">
<h3 class="text-lg font-semibold mt-6 mb-3"><strong>Green Book Cholera - FRCPath Part 2 – Revision Notes</strong></h3><p><strong>Topic : Cholera &amp; Cholera Vaccines (<em>Green Book</em> Ch 14, Aug 2024)</strong></p><h4 class="text-base font-semibold mt-4 mb-2"><strong>1 | Organism &amp; Pathogenesis</strong></h4><ul><li><em>Vibrio cholerae</em> serogroups <strong>O1 (El Tor &amp; classical) and O139</strong> cause epidemic disease; other serogroups rarely produce toxin .</li><li><strong>Cholera toxin</strong> → ↑cAMP → chloride secretion into intestine → massive isotonic fluid loss (“rice‑water” stools). </li><li>Incubation a few hours–5 days (median ≈ 2–3 d) .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>2 | Clinical Spectrum</strong></h4><table><tr><td><p><strong>Severity</strong></p></td><td><p><strong>Typical presentation</strong></p></td><td><p><strong>Key risks</strong></p></td></tr><tr><td><p>Mild / inapparent (≈ 80–90 %)</p></td><td><p>Self‑limited diarrhoea or asymptomatic carriage</p></td><td><p>None</p></td></tr><tr><td><p>Severe (10–20 %)</p></td><td><p>Profuse watery diarrhoea, vomiting, rapid dehydration → shock</p></td><td><p>Death within hours without IV/ORS </p></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>3 | Epidemiology &amp; Risk</strong></h4><ul><li><strong>Seventh pandemic (El Tor)</strong> ongoing since 1961; WHO noted global up‑surge mid‑2021 .</li><li>2022 WHO: ≥ 472 700 reported cases / 2 349 deaths; true burden 1.3–4 million cases &amp; 21 000–143 000 deaths .</li><li>UK: last home‑grown case 1893; mean 15 imported cases/yr 2015‑19, 20 in 2022 .</li><li>Travellers’ absolute risk in endemic areas ~2–3 per million .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>4 | Transmission &amp; Prevention Essentials</strong></h4><p>Faeco‑oral via contaminated water/food; raw seafood notable. </p><p>Risk ↑ with achlorhydria, pregnancy, malnutrition, blood group O.</p><p><strong>WASH</strong> measures (Water, Sanitation, Hygiene) remain cornerstone; vaccine is an adjunct .</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>5 | Public‑Health Actions (UK)</strong></h4><ul><li><strong>Notifiable disease</strong> – phone local Health Protection Team immediately on suspicion .</li><li>Manage cases with rehydration ± antibiotics; vaccines <strong>not used</strong> for ring vaccination or outbreak control in UK .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>6 | Vaccines Licensed in the UK (Table 14.1 abridged)</strong></h4><table><tr><td><p><strong>Attribute</strong></p></td><td><p><strong>Dukoral® (WC‑rCTB, killed)</strong></p></td><td><p><strong>Vaxchora® (CVD 103‑HgR, live)</strong></p></td></tr><tr><td></td><td><p class="mb-3"><strong>Recombinant cholera B toxin</strong></p></td><td></td></tr><tr><td><p>Age range</p></td><td><p>≥ 2 y</p></td><td><p>≥ 2 y</p></td></tr><tr><td><p>Primary course</p></td><td><p>≥ 6 y: 2 doses ≥ 1 wk apart; </p><p>2‑&lt;6 y: 3 doses ≥ 1 wk apart</p></td><td><p>Single dose</p></td></tr><tr><td><p>Complete <strong>≥ before travel</strong></p></td><td><p>1 wk</p></td><td><p>10 d</p></td></tr><tr><td><p>Booster</p></td><td><p>1 dose ≤ 2 y (≥ 6 y) or ≤ 6 m (2‑&lt;6 y); repeat full course if &gt;2 y / 6 m elapsed </p></td><td><p>None established </p></td></tr><tr><td><p>Efficacy</p></td><td><p>85 % at 6 m (Bangladesh); wanes to 26 % in 2–5 y by 36 m </p></td><td><p>90 % at 10 d, 80 % at 3 m (challenge study) </p></td></tr><tr><td><p>Shedding</p></td><td><p>None</p></td><td><p>11 % shed → hand‑wash × 14 d </p></td></tr><tr><td><p>Special notes</p></td><td><p>Some cross‑protection vs ETEC LT but <strong>not recommended</strong> for travellers’ diarrhoea </p><p>Can consider in breastfeeding due to killed</p></td><td><p>Live – avoid in immunosuppressed; </p><p>antibiotic avoid 14d pre and 10d post</p><p>chloroquine avoid 10d post</p></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>7 | Indications</strong></h4><ol><li><strong>Travellers</strong> at high risk (aid workers, outbreak areas lacking safe water/healthcare, underlying comorbidity) .</li><li><strong>Occupational</strong> – laboratory staff routinely handling <em>V. cholerae</em> .</li><li>Not required for international certificates since 1973 .</li></ol><p> <em>Vaccines </em><strong><em>not recommended</em></strong><em> in children &lt;2 y – no efficacy data</em> .</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>12 | Management of Cases &amp; Contacts (Exam Focus)</strong></h4><ul><li>Vaccine <strong>no role</strong> for contacts/outbreak control in UK – rely on hygiene &amp; source investigation .</li><li>Contacts should practise scrupulous hand hygiene.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>13 | High‑Yield Viva Pearls</strong></h4><ol><li><strong>“O‑one only”</strong> – both vaccines protect against O1, <strong>not O139 or other <em>Vibrio</em></strong> .</li><li>Live Vaxchora shedding → counsel on handwashing &amp; immunosuppressed contacts.</li><li>Restart Dukoral if &gt; 6 wks between doses; booster intervals differ by age .</li><li>Oral cholera vaccination <strong>not accepted</strong> for International Health Regulations certificates .</li><li>Cross‑protection vs ETEC LT exists but vaccine <strong>not</strong> advocated for travellers’ diarrhoea prophylaxis .</li></ol><h4 class="text-base font-semibold mt-4 mb-2"><strong>14 | Mnemonic – “CHO‑VAX SAFE”</strong></h4><p><strong>C</strong> holera toxin B vs live strain</p><p> <strong>H</strong> and hygiene still critical</p><p> <strong>O</strong> 1 only, not O139</p><p> <strong>V</strong> olume halve buffer (2‑&lt;6 y)</p><p> <strong>A</strong> void antibiotics / chloroquine near Vaxchora</p><p> <strong>X</strong> tra sodium caution</p><p> <strong>S</strong> chedules: 2‑3‑1 doses, restart &gt;6 wks</p><p> <strong>A</strong> id workers &amp; lab staff – main indications</p><p> <strong>F</strong> ridge 2–8 °C, Dukoral 14 d @ ≤25 °C</p><p> <strong>E</strong> licit boosters: ≤ 2 y or ≤ 6 m</p>
</div>